Diabetes drug company Sanofi-Aventis has made it clear that a final-stage study on its new type 2 diabetes drug has proved successful. The Phase III clinical trial results indicate that the drug, lixisentide, improve glycaemic control amongst patients with type 2 diabetes . The drug also reduces glucose in blood cells.
The drug will be part of the new diabetes drug class of GLP-1 inhibitors . Rivals in the class include Amylin, Byetta and Victoza . Some analysts claim that the drug is late to the field, but this remains to be seen.
The drug represents an attempt to broaden its diabetes offering, which currently includes blockbuster insulin Lantus . The new Sanofi diabetes division are trying to make the company more competitive in the fight against the disease. Marc Cluzel of Sanofi reportedly commented: “Developing new diabetes treatments, like lixisenatide, and helping patients achieve diabetes control is paramount to tackling the growing diabetes epidemic .”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…